83-5970-21　SARS-CoV-2 Spike, Sotrovimab Biosimilar 100ug　CAS No:2423014-07-5　592208

特徴

• Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2.
• Sotrovimab is a human monoclonal antibody (IgG1,k isotype).
• Sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab.
• sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19.
• It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection.
• The combination of two antibodies is intended to prevent mutational escape.
• sotrovimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Sotrovimab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.